NCT00049192: Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
|
|
| Completed | 2 | 43 | US | oblimersen sodium, augmerosen, G3139, G3139 bcl-2 antisense oligodeoxynucleotide, Genasense, imatinib mesylate, CGP 57148, Gleevec, Glivec, laboratory biomarker analysis | National Cancer Institute (NCI) | Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia | 11/05 | | | |
NCT00054639: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma |
|
|
| Completed | 2 | 48 | US | oblimersen sodium, augmerosen, G3139, G3139 bcl-2 antisense oligodeoxynucleotide, Genasense, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, laboratory biomarker analysis | National Cancer Institute (NCI) | Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia | 01/10 | 01/10 | | |
NCT00062244: Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia |
|
|
| Completed | 1/2 | 58 | US | oblimersen sodium, augmerosen, G3139, G3139 bcl-2 antisense oligodeoxynucleotide, Genasense | National Cancer Institute (NCI) | Waldenström Macroglobulinemia | 06/07 | | | |
